Media Articles Related to Maxalt-Mlt (Rizatriptan)
Positive data presented demonstrating erenumab significantly reduces monthly migraine days in patients with chronic migraine
Source: Clinical Trials / Drug Trials News From Medical News Today [2016.09.20]
Amgen has announced detailed global Phase 2 results showing erenumab demonstrated a statistically significant reduction in monthly migraine days compared with placebo in patients with chronic...
Sound Waves: An Rx for High Blood Pressure, Migraine?
Source: MedicineNet Clinical Trials Specialty [2016.09.19]
Title: Sound Waves: An Rx for High Blood Pressure, Migraine?
Category: Health News
Created: 9/16/2016 12:00:00 AM
Last Editorial Review: 9/19/2016 12:00:00 AM
Innovative sound therapy treats hypertension and migraine
Source: Headache / Migraine News From Medical News Today [2016.09.17]
A groundbreaking device that aligns the left and right brain using sound alone may reduce the symptoms of migraine, hypertension, and insomnia.
Spiritual meditation plus medication: The best medicine for migraines?
Source: Complementary Medicine / Alternative Medicine News From Medical News Today [2016.09.05]
"Effect of Different Meditation Types on Migraine Headache Medication Use," an article published in Behavioral Medicine, examines whether or not, and to what extent, a combination of spiritual...
Research on an fMRI-Based Neurologic Signature of Physical Pain to be Presented at Upcoming 10th Annual Pain & Migraine Therapeutics Summit
Source: Conferences News From Medical News Today [2016.08.16]
As persistent pain is solely measured by self-report, research is currently being conducted to find objective methods of identifying physical pain in the brain.
Published Studies Related to Maxalt-Mlt (Rizatriptan)
Efficacy and tolerability of rizatriptan for the treatment of acute migraine in sumatriptan non-responders. [2011.05]
OBJECTIVE: The study was carried out to assess the efficacy and tolerability of rizatriptan orally disintegrating tablet (ODT) for treating acute migraine in patients who are non-responders to sumatriptan. BACKGROUND: Many migraineurs report dissatisfaction with sumatriptan efficacy. It is unclear whether sumatriptan 100 mg non-responders will respond to other triptans... CONCLUSION: Rizatriptan 10-mg ODT was superior to placebo at providing two-hour pain relief and two-hour pain freedom in the treatment of acute migraine in those who do not respond to sumatriptan 100 mg. Rizatriptan was generally well tolerated in this population.
A double-blind, randomized, multicenter, Italian study of frovatriptan versus rizatriptan for the acute treatment of migraine. [2011.04]
The objective of this study was to assess patient satisfaction with acute treatment of migraine with frovatriptan or rizatriptan by preference questionnaire. 148 subjects with a history of migraine with or without aura (IHS 2004 criteria), with at least one migraine attack per month in the preceding 6 months, were enrolled and randomized to frovatriptan 2.5 mg or rizatriptan 10 mg treating 1-3 attacks...
Rizatriptan reduces vestibular-induced motion sickness in migraineurs. [2011.02]
A previous pilot study suggested that rizatriptan reduces motion sickness induced by complex vestibular stimulation. In this double-blind, randomized, placebo-controlled study we measured motion sickness in response to a complex vestibular stimulus following pretreatment with either rizatriptan or a placebo...
Efficacy of frovatriptan in the acute treatment of menstrually related migraine:
analysis of a double-blind, randomized, cross-over, multicenter, Italian,
comparative study versus rizatriptan. 
The objectives of this study are to assess the efficacy and safety of
frovatriptan, and rizatriptan in the subgroup of women with menstrually related
migraine of a multicenter, randomized, double blind, cross-over study. Each
patient received frovatriptan 2.5 mg or rizatriptan 10 mg in a randomized
sequence: after treating 3 episodes of migraine in not more than 3 months with
the first treatment, the patient had to switch to the other treatment...
A pilot study of rizatriptan and visually-induced motion sickness in migraineurs. [2009.08.06]
CONCLUSIONS: These pilot data suggest that rizatriptan does not consistently reduce visually-induced motion sickness in migraineurs. Rizatriptan may diminish motion sickness potentiation by cranial pain.
Clinical Trials Related to Maxalt-Mlt (Rizatriptan)
Drug Study in Pediatric Subjects With Migraines (MK0462-083 AM1) [Completed]
A study to assess the safety, tolerability, and single dose pharmacokinetics of a marketed
drug in pediatric subjects with migraines.
After completion of a portion of the study (Panels A and B), a regulatory agency issued an
amended request that the 12-17 year old age group studied should include a similar number of
male and female subjects. Therefore, the study was amended to add an additional panel of
subjects (Panel C) to ensure gender balance specifically in this age group.
Study of Rizatriptan in the Treatment of Acute Attacks of Post-traumatic Headache in U.S. Military Troops [Withdrawn]
Long-Term Exposure to Rizatriptan 5-mg and 10-mg Oral Tablet (Combined Extension Protocols MK-0462-022, MK-0462-025, MK-0462-029) [Completed]
Rizatriptan 5 mg and 10 mg, Sumatriptan 100 mg, and Placebo Comparison Study (0462-030) [Completed]
A study to compare rizatriptan 10 mg verse sumatriptan 100 mg in the treatment of migraine
attacks and duration of relief provided. This study will also provide additional efficacy
data on rizatriptan 5 mg and 10 mg for the treatment of migraine.
A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine in Children and Adolescents (MK-0462-082 AM7) [Completed]
Reports of Suspected Maxalt-Mlt (Rizatriptan) Side Effects
Drug Ineffective (3),
Intestinal Ischaemia (2),
Abdominal Pain (1),
Cardiac Tamponade (1),
Sudden Death (1),
Abortion Spontaneous (1),
Drug Label Confusion (1), more >>